Clostridium difficile colitis in an immunocompromised patient treated with fidaxomicin
The incidence of C. difficile-associated colitis has significantly increased in recent years in hospitals and long-term healthcare facilities. It has a great impact on morbidity and mortality, particularly in high-risk patients (e.g. elderly and subjects with comorbidities or immunosuppression), who...
Main Author: | Marcello Feasi |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd
2015-05-01
|
Series: | Clinical Management Issues |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1039 |
Similar Items
-
Fidaxomicin in the treatment of colitis due to Clostridium difficile: preliminary results
by: Francesco Cortese, et al.
Published: (2014-12-01) -
Toxic megacolon associated with Clostridium difficile infection recurrence: a case report complicated by multiple bacterial infections and successfully treated with oral fidaxomicin
by: Addolorata Masiello, et al.
Published: (2014-12-01) -
Recurrent Clostridium difficile colitis in elderly: the role of fidaxomicin
by: Francesco Artom, et al.
Published: (2014-12-01) -
Fidaxomicin - the new drug for Clostridium difficile infection
by: Chetana Vaishnavi
Published: (2015-01-01) -
High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China
by: Jing-Wei Cheng, et al.
Published: (2018-06-01)